Guardian Pharmacy (GRDN) director awarded 8,952 restricted stock units vesting 2029

Rhea-AI Filing Summary

Morris David K reported acquisition or exercise transactions in this Form 4 filing.

Guardian Pharmacy Services, Inc. director and officer Morris David K reported an equity award of 8,952 shares of Class A common stock on March 1, 2026. The award is in the form of restricted stock units granted at $0.00 per share, bringing his directly held Class A shares to 442,327.

The footnote explains these are restricted stock units that settle one-for-one into Class A common stock when they vest in full on March 1, 2029, highlighting that the award’s value depends on future vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morris David K

(Last) (First) (Middle)

300 GALLERIA PARKWAY SE, SUITE 800

(Street)

ATLANTA GA 30339

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardian Pharmacy Services, Inc. [ GRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/01/2026		A		8,952(1)	A	$0.00	442,327	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of restricted stock units that upon vesting are settled on a one-for-one basis in shares of Class A common stock, vesting in full on March 1, 2029.

Remarks:

Executive Vice President and Chief Financial Officer

	/s/ Douglas Towns, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did GRDN report for Morris David K?

Guardian Pharmacy Services reported that Morris David K received an equity award of 8,952 shares of Class A common stock on March 1, 2026. This was coded as a grant or award acquisition, increasing his directly held Class A position to 442,327 shares after the transaction.

Was the GRDN insider award to Morris David K a purchase or a grant?

The transaction is a grant, not an open-market purchase. It is coded as a grant, award, or other acquisition at a price of $0.00 per share, reflecting restricted stock units rather than shares bought for cash in the market.

How many GRDN shares does Morris David K hold after this Form 4?

After the reported grant, Morris David K directly holds 442,327 shares of Guardian Pharmacy Services Class A common stock. This figure includes the newly awarded 8,952 restricted stock units that are scheduled to settle into shares when they vest in the future.

What are the terms of the GRDN restricted stock units granted to Morris David K?

The award consists of restricted stock units that settle one-for-one into Class A common stock. According to the footnote, these units vest in full on March 1, 2029, meaning the underlying shares become deliverable only after that vesting date is reached.

When will the GRDN restricted stock units for Morris David K fully vest?

The restricted stock units granted to Morris David K are scheduled to vest in full on March 1, 2029. Upon vesting, they will be settled one-for-one in shares of Guardian Pharmacy Services Class A common stock, according to the disclosure’s footnote.